About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals is a company based in Lexington (United States) founded in 2007 was acquired by Novo Nordisk in November 2021. Dicerna Pharmaceuticals has raised $106.45 million across 7 funding rounds from investors including Lilly, Novo Nordisk and RA Capital. The company has 337 employees as of December 31, 2021. Dicerna Pharmaceuticals offers products and services including Wegovy and Ozempic. Dicerna Pharmaceuticals operates in a competitive market with competitors including Alnylam, Denali Therapeutics, Avidity Biosciences, Poseida Therapeutics and Castle Biosciences, among others.
- Headquarter Lexington, United States
- Employees 337 as on 31 Dec, 2021
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dicerna Pharmaceuticals Inc
-
Annual Revenue
$164.31 M (USD)587as on Dec 31, 2020
-
Net Profit
-$112.75 M (USD)6as on Dec 31, 2020
-
EBITDA
-$113.21 M (USD)12as on Dec 31, 2020
-
Total Equity Funding
$106.45 M (USD)
in 7 rounds
-
Latest Funding Round
$100 M (USD), Post-IPO
Dec 19, 2018
-
Investors
Lilly
& 16 more
-
Employee Count
337
as on Dec 31, 2021
-
Acquired by
Novo Nordisk
(Nov 18, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Dicerna Pharmaceuticals
Dicerna Pharmaceuticals offers a comprehensive portfolio of products and services, including Wegovy and Ozempic.
Medication for weight management in adults with obesity.
Drug for managing type 2 diabetes and related conditions.
People of Dicerna Pharmaceuticals
Unlock access to complete
Unlock access to complete
Leadership Team
275 people
Software Development Team
233 people
Senior Team
108 people
Product Management Team
58 people
Finance and Accounting
53 people
Human Resources and Administration
53 people
Operations Team
44 people
Data Analysis and Operations Team
42 people
Unlock access to complete
Funding Insights of Dicerna Pharmaceuticals
Dicerna Pharmaceuticals has successfully raised a total of $106.45M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Dicerna Pharmaceuticals
Dicerna Pharmaceuticals has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Novo Nordisk and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life science & tech focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
US life sciences companies are invested in by Skyline Ventures.
|
Locked | Locked | Locked | |
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Locked | Locked | Locked |
Investor details for Dicerna Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Dicerna Pharmaceuticals
Investment portfolio details for Dicerna Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Dicerna Pharmaceuticals
Detailed financials for Dicerna Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dicerna Pharmaceuticals Comparisons
Peer comparison for Dicerna Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Dicerna Pharmaceuticals
Dicerna Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alnylam, Denali Therapeutics, Avidity Biosciences, Poseida Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
Detailed competitors of Dicerna Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dicerna Pharmaceuticals
Complete news archive for Dicerna Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dicerna Pharmaceuticals
Dicerna Pharmaceuticals was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Dicerna Pharmaceuticals is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Dicerna Pharmaceuticals is a funded company, having raised a total of $106.45M across 7 funding rounds to date.
As of Dec 31, 2021, the latest employee count at Dicerna Pharmaceuticals is 337.
Annual revenue of Dicerna Pharmaceuticals is $164.31M as on Dec 31, 2020.
Founded in 2007, Dicerna Pharmaceuticals is based in Lexington, United States, within the biotechnology sector. Therapeutics are developed through RNA interference technology for various conditions. A lead RNA product targets hepatocellular carcinoma, while other candidates address primary hyperoxaluria, genetic liver diseases, cardiovascular issues, and hepatitis B virus. The GalXC platform is applied to silence genes associated with these diseases.
Dicerna Pharmaceuticals's top competitors include Juno Therapeutics, Alnylam and Avidity Biosciences.
Dicerna Pharmaceuticals offers Wegovy and Ozempic.
Dicerna Pharmaceuticals has 17 investors. Key investors include Lilly, Novo Nordisk, RA Capital, Bain Capital Private Equity, and Abingworth.